The Immunitrack Mission

Our mission is to assist biotech and pharma companies in producing new biologics and vaccines faster, cheaper, more effectively and safer.

The Immunitrack History

Our company builds on more than twelve years of experience in performing and optimizing in vitro MHC/epitope binding assays for MHC I and MHC II.

Co-founder and Immunitrack CSO, Sune Justesen, was in charge of developing one of the largest in vitro assay platforms for measuring peptide binding to MHC ever developed. The platform was used to perform a total of 200,000 Kd measurements on 150 MHC alleles. The data was then used to develop the allele-specific predictor NetMHC allele-specific prediction software, still widely used in immune system analysis.

Since its founding in 2013, Immunitrack has developed its unique NeoScreen® platform, providing researchers with a better tool for assessing the immunogenicity of epitopes.

Management Team

Sune Justesen CSO

Sune Justensen PhD
Chief Scientific Officer

Sune Justensen founded Immunitrack together with Stephan Thorgrimsen in 2013. A civil engineer from the Technical University of Denmark, Sune later completed a PhD as well as postdoctoral training in one of the world’s leading groups within major histocompatibility complexes (MHC) at the University of Copenhagen, Denmark. Sune is a world-leading expert in MHC, a family of receptors that are central to the immune response. During his research career, he devised novel ways to produce functional MHC molecules and analyse MHC-epitope interactions through a range of unique assays. This groundbreaking work positioned his then research group as a global leader in the MHC field and simultaneously led to the technology upon which Immunitrack is founded.

Stephan Thorgrimsen CEO

Stephan Thorgrimsen PhD
Chief Executive Officer

Stephan Thorgrimsen is one of Immunitrack’s two co-founders. He holds a PhD in biochemistry from the University of Copenhagen, Denmark and he authored or co-authored numerous peer-reviewed articles during his research career. In 2013, Stephan completed an MBA from the prestigious Copenhagen Business School and cofounded Immunitrack where he currently is the CEO.

Board of Directors

Robin Campbell

Robin Campbell PhD
Board Director

Robin Campbell holds a degree in Microbiology from King’s College London, and a PhD in immunobiology from Liverpool University. He has supported pharma and biotech companies in securing public and private financing for more than 30 years. He has also helped to list companies onto the UK’s AIM and other international exchanges, as well as advised on secondary fundraisings, private equity raises, and mergers and acquisitions.

He has a broad reach into institutional and retail investor networks. Robin recently joined Immunitrack’s board, following a previous role as chairman of the board at Hemogenyx Pharmaceuticals Plc (London), after helping support Hemogenyx achieve a public listing on the London Stock Exchange in 2017.

Scientific Advisors